TGFB1 and glioblastoma: Importantly, reduced TGF-β1 secretion by EGFRvIII U87 cells upon knockdown of SPP resulted in less pro-tumorigenic SMAD signalling in normal glioblastoma cells treated with the supernatant of these cells thereby reducing their invasive capacity [96].